Globestar Therapeutics (GSTC) Stock Price, News & Analysis
Company Description
Globestar Therapeutics (OTC Link: GSTC) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $124.1K.
This page collects what Stock Titan holds for GSTC, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Globestar Therapeutics (GSTC) stock last closed at $0.0000. At a market capitalization of $124.1K, GSTC is classified as a micro-cap stock with approximately 1.2B shares outstanding.
Latest News
Globestar Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 4 with negative movement. Key topics include clinical trial. View all GSTC news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Globestar Therapeutics (GSTC) currently stands at 37.8 thousand shares, representing 0.0% of the float. This relatively low short interest suggests limited bearish sentiment. With 19.8 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Globestar Therapeutics (GSTC) currently stands at 19.8 days, down 8.8% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 142.1% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
GSTC Company Profile & Sector Positioning
Globestar Therapeutics (GSTC) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing GSTC often look at related companies in the same sector, including Tracon Pharmaceu (TCON), Endonovo Therape (ENDV), Scorpius Holdings (SCPX), Panbela Therapeutics Inc (PBLA), and Trevena Inc (TRVN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GSTC's relative position within its industry.